<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928094</url>
  </required_header>
  <id_info>
    <org_study_id>CT-3-003</org_study_id>
    <nct_id>NCT02928094</nct_id>
  </id_info>
  <brief_title>Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia</brief_title>
  <acronym>AFFIRM</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Ad5FGF-4 in Patients With Refractory Angina Due to Myocardial Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angionetics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huapont Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Angionetics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a single intracoronary infusion of an&#xD;
      adenovirus serotype 5 virus expressing the gene for human fibroblast growth factor-4&#xD;
      (Ad5FGF-4) is effective in improving angina-limited exercise duration, angina functional&#xD;
      class, frequency of angina attacks, frequency of nitroglycerin usage, and quality of life.&#xD;
      Half of the study participants will receive Ad5FGF-4, and half will receive placebo. The&#xD;
      primary endpoint is the change from baseline to Month 6 in Exercise Tolerance Test (ETT)&#xD;
      duration. Long-term safety of Ad5FGF-4 will also be assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Exercise Tolerance Test (ETT) duration</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Modified Bruce Protocol with exercise duration limited by angina or angina equivalent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in patient functional status (CCS class)</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Canadian Cardiovascular Society (CCS) angina classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weekly angina frequency</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Average weekly angina episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weekly nitroglycerin usage</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Average weekly nitroglycerin usage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Seattle Angina Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Ad5FGF-4</measure>
    <time_frame>Through Month 6</time_frame>
    <description>Adverse events and clinical laboratory testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term safety of Ad5FGF-4</measure>
    <time_frame>Through Month 60</time_frame>
    <description>Occurrence of clinically significant events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Angina, Stable</condition>
  <arm_group>
    <arm_group_label>A: Ad5FGF-4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad5FGF-4, administered one time at 6x10e9 viral particles in buffer, and maximally-tolerated medical therapy for angina.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo buffer, administered one time, and maximally-tolerated medical therapy for angina.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad5FGF-4</intervention_name>
    <description>Ad5FGF-4 administered via intracoronary infusion using standard balloon catheter, and under conditions of transient ischemia.</description>
    <arm_group_label>A: Ad5FGF-4</arm_group_label>
    <other_name>Generx</other_name>
    <other_name>alferminogene tadenovec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo buffer administered via intracoronary infusion using standard balloon catheter, without transient ischemia.</description>
    <arm_group_label>B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients 55-75 years of age inclusive&#xD;
&#xD;
          2. Refractory angina CCS Class III or IV&#xD;
&#xD;
          3. At least 3 angina episodes per week&#xD;
&#xD;
          4. Diagnostic coronary angiogram in the past 12 months confirming the presence of&#xD;
             coronary artery disease in patients who are not candidates for standard interventions&#xD;
             (PCI or CABG)&#xD;
&#xD;
          5. Patients without significant and adequate reduction or relief of angina in spite of&#xD;
             treatment with at least two functional classes of chronic anti-angina medication at&#xD;
             the maximally tolerated dose. Functional classes of anti-angina medications include&#xD;
             β-blockers, calcium channel blockers, nitrates, and metabolic modulators (i.e.&#xD;
             ranolazine). Participants must have been on a stable anti-angina medication regimen&#xD;
             for at least 4 weeks before signing the informed consent form.&#xD;
&#xD;
          6. Documented clinical evidence of inducible ischemia on stress testing within the past 6&#xD;
             months [e.g. nuclear perfusion imaging (stress SPECT or PET), stress ECHO, stress MRI,&#xD;
             stress ETT (≥1 mm ST Segment depression)].&#xD;
&#xD;
          7. Maximal exercise duration of 3-8 minutes on ETT (Modified Bruce Protocol), with&#xD;
             patient physically unable to continue due to angina or angina equivalent (e.g.&#xD;
             exhaustion/dyspnea), or when ETT is stopped by person administering the ETT. Patient&#xD;
             develops ≥1mm ST segment depression on each of the qualifying baseline ETT&#xD;
&#xD;
          8. Left ventricular ejection fraction (LVEF) of ≥ 30%&#xD;
&#xD;
          9. Postmenopausal female patients, women of childbearing potential and men willing to use&#xD;
             an effective contraception method while in the study and/or who agree not to become&#xD;
             pregnant or make their partner pregnant throughout the study and during one year after&#xD;
             administration of the study drug&#xD;
&#xD;
         10. Female subjects of childbearing potential who have a negative urine pregnancy test and&#xD;
             are willing to use an acceptable form of birth control during the study. For the&#xD;
             purpose of this study, a female of childbearing potential is a female who is not&#xD;
             postmenopausal for greater than 2 years, has not had a tubal ligation, and has not had&#xD;
             a hysterectomy. For the purpose of this study, the following are considered acceptable&#xD;
             methods of birth control:&#xD;
&#xD;
               -  Oral contraceptives, contraceptive patches/implants&#xD;
&#xD;
               -  Intrauterine device (IUD) together with condom or spermicide for at least three&#xD;
                  months&#xD;
&#xD;
               -  Condom and spermicide&#xD;
&#xD;
               -  Abstinence with a documented second acceptable method of birth control should the&#xD;
                  subject become sexually active&#xD;
&#xD;
         11. Willing and able to comply with all study requirements, including adherence to the&#xD;
             assigned strategy, medical therapy, and follow-up&#xD;
&#xD;
         12. Provided written informed consent&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Female patients who are pregnant, lactating (breast milk feeding), or planning a&#xD;
             pregnancy during the course of the study and one year after administration of the&#xD;
             study drug. Women of childbearing potential who are not using an acceptable method of&#xD;
             birth control (i.e., IUD, oral contraceptive plus barrier contraceptive, hormone&#xD;
             delivery system plus barrier contraceptive or condom in combination with contraceptive&#xD;
             cream, jelly or foam). Women of childbearing potential with a positive urine pregnancy&#xD;
             test (minimum sensitivity 25 IU/L or equivalent units of HCG) before randomization.&#xD;
&#xD;
          2. Patients with unstable angina for whom an immediate revascularization procedure (PCI&#xD;
             or CABG) is indicated&#xD;
&#xD;
          3. Patients for whom a cardiac revascularization procedure (PCI or CABG) is planned in&#xD;
             the next 3 months&#xD;
&#xD;
          4. Myocardial infarction within the past 3 months prior to the Screening visit&#xD;
&#xD;
          5. Congestive heart failure New York Heart Association (NYHA) Class IV&#xD;
&#xD;
          6. Myocarditis or restrictive pericarditis&#xD;
&#xD;
          7. Diagnostic coronary angiogram finding of left main coronary stenosis ≥70% (unless the&#xD;
             patient has a patent graft or collateral vessels supplying the left coronary&#xD;
             circulation) or proximal stenoses ≥70% in all major coronary conduit vessels (coronary&#xD;
             arteries and bypass grafts)&#xD;
&#xD;
          8. A single patent coronary conduit (for example, totally occluded RCA and LCx with no&#xD;
             bypass grafts. Patient will not tolerate balloon occlusion of the LAD for infusion)&#xD;
&#xD;
          9. Patients whose angiogram shows a good anatomy for angioplasty and who are candidates&#xD;
             for that procedure. Patients without a prior angiogram or angiogram report are&#xD;
             excluded.&#xD;
&#xD;
         10. Clinically significant aortic or mitral valvular heart disease&#xD;
&#xD;
         11. Life-threatening coronary ostial stenosis that precludes adequate catheter engagement&#xD;
             in any target vessel, unless the vessel can be accessed via a patent bypass graft&#xD;
&#xD;
         12. Coronary artery to venous communications, which bypass the coronary capillary bed&#xD;
&#xD;
         13. Untreated life-threatening ventricular arrhythmias&#xD;
&#xD;
         14. Uncontrolled arterial hypertension with systolic blood pressure &gt;140 mm Hg and/or&#xD;
             diastolic pressure &gt;100 mm Hg&#xD;
&#xD;
         15. CABG surgery within the past 6 months, unless those grafts are now occluded&#xD;
&#xD;
         16. Percutaneous coronary intervention (PCI) within the past 3 months, unless the&#xD;
             stented/dilated vessel(s) are now occluded&#xD;
&#xD;
         17. Enhanced external counterpulsation (EECP) within 3 months prior to the start of&#xD;
             screening evaluations&#xD;
&#xD;
         18. Prior treatment with spinal cord stimulation&#xD;
&#xD;
         19. Prior treatment with coronary sinus reducer&#xD;
&#xD;
         20. Transmyocardial or percutaneous myocardial laser revascularization within the past 12&#xD;
             months&#xD;
&#xD;
         21. Prior treatment with any cardiovascular gene or cell therapy within the past 12 months&#xD;
&#xD;
         22. Active SARS-CoV-2 infection (COVID-19)&#xD;
&#xD;
         23. Any major organ disease or any medical disease or condition that substantially impairs&#xD;
             life expectancy&#xD;
&#xD;
         24. History of cancer within the past 5 years, other than basal cell carcinoma, or&#xD;
             patients with any laboratory or physical exam or diagnostic procedure finding&#xD;
             suggestive of current malignancy&#xD;
&#xD;
         25. Moderate to severe non-proliferative or proliferative retinopathy from any cause,&#xD;
             clinically significant macular edema, or previous pan-retinal photocoagulation therapy&#xD;
&#xD;
         26. Heparin induced thrombocytopenia or history of idiopathic thrombocytopenic purpura or&#xD;
             other medical condition causing thrombocytopenia&#xD;
&#xD;
         27. Serum glutamic pyruvic transaminase (SGPT) level greater than 2.0 times the upper&#xD;
             limit of the laboratory normal range.&#xD;
&#xD;
         28. Bilirubin level ≥ 2.0 mg/dL&#xD;
&#xD;
         29. Serum creatinine ≥ 2.5 mg/dL&#xD;
&#xD;
         30. Platelet count &lt; 100,000/μL&#xD;
&#xD;
         31. White blood cell count &lt; 3,000/μL&#xD;
&#xD;
         32. HbA1c &gt; 9% in patients with diabetes&#xD;
&#xD;
         33. Positive test for hepatitis B or C&#xD;
&#xD;
         34. Positive test for human immunodeficiency virus (HIV)&#xD;
&#xD;
         35. Prior anaphylaxis reaction to iodinated contrast agents&#xD;
&#xD;
         36. Patients who are known to be immunosuppressed or are receiving chronic treatment with&#xD;
             immunosuppressive drugs&#xD;
&#xD;
         37. Received an investigational drug or biologic within 30 days of screening or are&#xD;
             currently participating in an investigational drug, biologic or device trial&#xD;
&#xD;
         38. History of alcohol or drug abuse&#xD;
&#xD;
         39. History of non-compliance with medical therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lois A Chandler, PhD</last_name>
    <phone>858-386-8416</phone>
    <email>lchandler@angionetics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christopher Reinhard</last_name>
    <phone>858-414-1477</phone>
    <email>creinhard@angionetics.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Henry TD, Grines CL, Watkins MW, Dib N, Barbeau G, Moreadith R, Andrasfay T, Engler RL. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol. 2007 Sep 11;50(11):1038-46. Epub 2007 Aug 24.</citation>
    <PMID>17825712</PMID>
  </reference>
  <reference>
    <citation>Grines CL, Watkins MW, Mahmarian JJ, Iskandrian AE, Rade JJ, Marrott P, Pratt C, Kleiman N; Angiogene GENe Therapy (AGENT-2) Study Group. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol. 2003 Oct 15;42(8):1339-47.</citation>
    <PMID>14563572</PMID>
  </reference>
  <reference>
    <citation>Rubanyi GM. Angiogenic gene therapy for refractory angina. Expert Opin Biol Ther. 2016;16(3):303-15. doi: 10.1517/14712598.2016.1122753. Epub 2015 Dec 14. Review.</citation>
    <PMID>26581236</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 6, 2016</study_first_submitted>
  <study_first_submitted_qc>October 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2016</study_first_posted>
  <last_update_submitted>April 25, 2021</last_update_submitted>
  <last_update_submitted_qc>April 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory angina</keyword>
  <keyword>myocardial ischemia</keyword>
  <keyword>angiogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

